EMERYVILLE, Calif.--(BUSINESS WIRE)--The Vice-President of Research, Dr. Nafsika Georgopapadakou of NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, www.novabaypharma.com), a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial, fungal, and viral infections, contributed an article to the April 2008 issue of Pharmaceutical Formulation & Quality magazine. The article, entitled “Are We Headed to a Post-Antibiotic Era?,” elaborates on the need for new therapeutics to treat and prevent methicillin-resistant Staphylococcus aureus (MRSA) and other infection that have become resistant to antibiotics. It reviewed NovaBay’s compound, NVC-422, which is currently being developed as a response to this growing problem.
